Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex 10% IVIg for Demyelination and Diabetes
NCT02372149Phase 4Unknown
- Sponsor
- University of Toronto
- Start
- Feb 2015
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by University of Toronto. Status: unknown.
02
Drugs
intravenous human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02372149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372149.